Author

Mohammad Ahmad

Institution: Ascentage Pharma Group Inc. (United States)

Observed institution: Ascentage Pharma Group Inc. (United States)

OpenAlex ID: A5026254366

Lisaftoclax (APG-2575) Safety and Activity As Monotherapy or Combined with Acalabrutinib or Rituximab in Patients (pts) with Treatment-Naïve, Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (R/R CLL/SLL): Initial Data from a Phase 2 Global Study

2022 · Matthew S. Davids, Asher Chanan-Khan, et al. · Blood · 16

Lisaftoclax (APG-2575) Demonstrates Activity and Safety When Given with Accelerated Ramp-up and then Combined with Acalabrutinib or Rituximab in Patients (pts) with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Including Those with Prior Exposure to Venetoclax

2024 · Matthew S. Davids, Sikander Ailawadhi, et al. · Blood · 9

Safety, tolerability, and pharmacokinetics of lisaftoclax (APG-2575)-based therapy in patients with chronic lymphocytic leukemia: Phase 1b/2 study

2025 · Matthew S. Davids, Asher Chanan-Khan, et al. · Med · 7

Results of the APG2575AU101 Study of lisaftoclax (APG-2575) combined with azacitidine (AZA) in patients with newly diagnosed (ND) or prior venetoclax–exposed myeloid malignancies

2025 · Tapan Kadia, Patricia Kropf, et al. · Blood · 4

Trial in Progress: Phase 1b/2 Study of Alrizomadlin (APG-115), Alone or Combined with 5-Azacitidine (AZA), in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML), or Myelodysplastic Syndrome (MDS)

2022 · Tapan M. Kadia, Christopher Benton, et al. · Blood · 4

Phase 1b/2 study of lisaftoclax (APG-2575) combined with azacitidine (AZA) in patients (pts) with treatment-naïve (TN) or prior venetoclax (VEN)-exposed myeloid malignancies.

2025 · Michael Francis Leahy, Shaun Fleming, et al. · Journal of Clinical Oncology · 3

POSTER: AML-743 Phase 1b/2 Study of Lisaftoclax (APG-2575) Combined With Azacitidine in Patients With Newly Diagnosed (ND) or Prior Venetoclax-Exposed Myeloid Malignancies

2025 · Michael Francis Leahy, Shaun Fleming, et al. · Clinical Lymphoma Myeloma & Leukemia

AML-743: Phase 1b/2 Study of Lisaftoclax (APG-2575) Combined With Azacitidine in Patients With Newly Diagnosed (ND) or Prior Venetoclax-Exposed Myeloid Malignancies

2025 · Michael Francis Leahy, Shaun Fleming, et al. · Clinical Lymphoma Myeloma & Leukemia

Works count: 8

Citation count: 43

H-index: 4

I10-index: 1